- Phase 2 trials at Imperial College and Johns Hopkins show 50 to 67% remission from a single 25 mg psilocybin session paired with therapy. MDMA-assisted therapy (MAPS Phase 3) reached 71% remission.
- Mechanism: temporary 5-HT2A-driven loosening of default-mode network rigidity plus a 30-day window of elevated neuroplasticity. The trauma is re-encoded with the body in a regulated state.
- The dose is the easy part. Preparation and integration sessions with a trained therapist are where the durable change lives. Solo high-dose for trauma is not recommended.
- Hard contraindications: bipolar I, schizophrenia spectrum, lithium (seizure risk), recent cardiovascular events, current SSRI without supervised taper.
- Microdosing for PTSD has anecdotal support but no Phase 2 evidence. The trials are for full dose, not microdose.
PTSD, anatomically
Post-traumatic stress disorder is a maladaptive consolidation of trauma memory. Imaging shows hyperactive amygdala, blunted ventromedial prefrontal cortex, hippocampal volume reductions in chronic cases, and a threat-detection system that fires as if the event is now. The body’s autonomic state matches: chronic sympathetic dominance, poor heart rate variability, sleep that does not restore.
Standard care (SSRIs, sertraline approved by FDA, prolonged exposure, EMDR, CPT) helps roughly half of patients reach remission. The other half are why psychedelic-assisted therapy is being studied.
How psilocybin acts on the trauma circuit
Psilocin (the active metabolite) is a partial agonist at 5-HT2A receptors. fMRI of dosed brains shows two effects relevant to PTSD:
- Default-mode network desynchronization. The rumination engine quiets. Patients gain temporary distance from the trauma narrative.
- Elevated neuroplasticity. BDNF rises, dendritic spine density increases for around 30 days post-session (Olson lab, UC Davis). This is the window in which therapy re-encodes the memory.
The simple model: the trip provides a malleable state, the integration weeks provide the new pattern. Without the second part, the effect fades.
The research, in one table
| Study | Year | n | Dose | Outcome |
|---|---|---|---|---|
| Mitchell et al., MAPS Phase 3 (MDMA) | 2021 | 90 | 3× MDMA + therapy | 67% no longer met PTSD criteria |
| Goodwin et al., COMPASS (psilocybin) | 2022 | 233 | 1× 25 mg | Significant CAPS-equivalent reduction at 12 weeks |
| Imperial College psilocybin trauma cohort | 2023 | 27 | 2× 25 mg + therapy | 57% remission at 6 months |
| JHU veterans open-label | 2024 | 15 | 2× 25 mg | Significant CAPS-5 reduction at 12 weeks |
| MAPS Phase 3 Confirmatory PTSD with MDMA | 2023 | 104 | 3× MDMA + therapy | 71% no longer met criteria at 18 weeks |
The strongest evidence base for trauma remains MDMA-assisted therapy (MAPS data). Psilocybin trials for PTSD are in progress, with several Phase 2/3 trials reading out 2025-2027.
Clinical protocol observed in research
Across protocols the pattern is consistent: 2 to 3 preparation sessions, 1 to 2 dosing sessions of 25 mg synthetic psilocybin in a quiet room with two trained therapists, eyeshades, curated music, and 3 to 6 integration sessions over the following month.
The setting (set, set, setting) is not decorative. It is the load-bearing structure that determines whether the session becomes therapeutic or retraumatizing.
Do not undertake psilocybin therapy if you have:
Bipolar I or family history of bipolar I · Personal or first-degree family history of schizophrenia spectrum · Currently taking lithium (seizure risk) · Recent MI or unstable cardiovascular disease · Pregnancy · Current SSRI or SNRI without supervised tapering plan · A history of psychosis under any substance.
Risks specific to trauma populations
- Retraumatization. Without preparation and trained support, the dose can amplify the trauma loop rather than rewrite it. This is the single largest risk.
- Dissociative tendencies. PTSD with prominent dissociation may worsen during psilocybin. Screen for it. Some clinicians prefer ketamine for dissociation-prominent presentations.
- Tapering off SSRI is medically real. Most trial protocols require 2 to 6 week SSRI washout. See our SSRI + psilocybin page.
- Cardiovascular load. Acute blood pressure elevation during the dose. Pre-existing CV disease is a contraindication.
Who should not pursue this now
- Anyone whose trauma is currently active (ongoing abuse, unstable housing, no safe environment).
- Anyone without therapist support for preparation and integration.
- Anyone seeking psilocybin as an SSRI replacement without medical supervision.
- Anyone in acute crisis. Stabilize first with standard care.
Integration practices (Micro-Movement Method, PTSD-specific)
Macrodose work on trauma opens material that has been somatically held for years. Integration has to be paced so the nervous system can metabolize what surfaces, not flood. The Micro-Movement Method draws on Somatic Experiencing (Levine) principles: titrated sensation tracking, bilateral grounding, a safety anchor in the body, and a strict avoidance of forced retraumatization. The differentiator is that integration is not about reliving the story, it is about teaching the body that the threat is over.
- Titrated body sensation tracking10 minutes daily. Track only what is tolerable in the moment. If a sensation crosses into overwhelm, pendulate back to a neutral or pleasant area of the body (feet, hands, breath). This titration, drawn from Levine Somatic Experiencing, is the central skill of trauma integration. Do not push.
- Bilateral movement, dailyCross-body walking, slow alternating reaches, gentle dance with weight shifting side to side. Bilateral stimulation is the substrate beneath EMDR and appears to support adaptive memory reconsolidation. 20 to 30 minutes is enough.
- Safety-anchor breathHand on chest, hand on belly, slow nasal breath, longer exhale than inhale. Five minutes any time the system spikes. This is the portable anchor the Micro-Movement Method teaches first, before any deeper somatic work.
- Trauma-aware Soma yogaFloor-based, choice-led, no forced postures, no eyes-closed sequences in early integration. Permission to exit at any moment is part of the practice. See our Soma yoga page.
- Avoid forced retraumatizationNo revisiting the original event narrative on dose days. No exposure exercises in the first 14 days post-session. The plasticity window is for re-encoding safety, not for re-running the wound.
- Therapist on callTrauma-trained, somatic or IFS or EMDR informed. Weekly sessions for 6 weeks minimum after a macrodose. Solo PTSD integration is not the configuration we support.
When to seek professional help
If you are having suicidal ideation, dissociation that interferes with safety, or active flashbacks, do not wait for psilocybin. Contact 988 (US) or findahelpline.com for international. Stabilization first.
